

Suzanne Trudel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9696404/publications.pdf>

Version: 2024-02-01

43
papers

3,563
citations

623699

14
h-index

345203

36
g-index

43
all docs

43
docs citations

43
times ranked

5468
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011, 471, 467-472.	27.8	1,288
2	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2012, 120, 2817-2825.	1.4	608
3	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	10.7	544
4	CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. <i>Blood</i> , 2005, 105, 2941-2948.	1.4	268
5	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1641-1653.	10.7	193
6	Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. <i>Blood Cancer Journal</i> , 2019, 9, 37.	6.2	171
7	The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan. <i>Clinical Cancer Research</i> , 2007, 13, 621-629.	7.0	116
8	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. <i>Blood</i> , 2018, 131, 855-863.	1.4	105
9	Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.. <i>Blood</i> , 2007, 110, 411-411.	1.4	29
10	Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 2668-2673.	1.3	27
11	Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. <i>Cancer Medicine</i> , 2017, 6, 3-11.	2.8	24
12	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , 2021, 17, 1987-2003.	2.4	23
13	First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. <i>Blood</i> , 2016, 128, 1148-1148.	1.4	23
14	Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. <i>Bone Marrow Transplantation</i> , 2020, 55, 578-585.	2.4	17
15	Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium. <i>Blood</i> , 2016, 128, 4526-4526.	1.4	17
16	Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. <i>Future Oncology</i> , 2020, 16, 2783-2798.	2.4	12
17	A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). <i>Clinical Cancer Research</i> , 2021, 27, 5028-5037.	7.0	12
18	Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. <i>Nature Communications</i> , 2021, 12, 6322.	12.8	12

#	ARTICLE	IF	CITATIONS
19	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 387-394.	0.4	11
20	Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3â€‰mL per injection site. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 285-292.	0.9	9
21	<i>Listeria</i> Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy. <i>JAMA Oncology</i> , 2020, 6, 293.	7.1	9
22	Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134. <i>Clinical Cancer Research</i> , 2011, 17, 4693-4704.	7.0	7
23	Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 225-234.	0.4	7
24	Addition of Cyclophosphamide â€œOn Demandâ€ to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myelomaâ€”A Retrospective Review of a Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e195-e203.	0.4	4
25	A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1721-1729.	1.3	4
26	CHIR-258 Efficacy in a Newly Developed Preclinical Bone Marrow Model of t(4;14) Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3449-3449.	1.4	4
27	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2013, 122, 3231-3231.	1.4	3
28	An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 4163-4163.	1.4	3
29	Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting. <i>Blood</i> , 2016, 128, 2137-2137.	1.4	3
30	Incorporating isatuximab in the treatment of multiple myeloma. <i>Lancet, The</i> , 2019, 394, 2045-2047.	13.7	2
31	Evaluation of XL999, a Potent Inhibitor of FGFR3, for the Potential Treatment of t(4;14) Positive Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2515-2515.	1.4	2
32	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. <i>Blood</i> , 2021, 138, 3055-3055.	1.4	2
33	Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study. <i>Blood</i> , 2019, 134, 4570-4570.	1.4	1
34	A Rapid Desensitization Program Is a Viable Therapeutic Option in the Management of Immunomodulating Agent-Related Hypersensitivity Reactions in Patients with Plasma Cell Disorders. <i>Blood</i> , 2016, 128, 2411-2411.	1.4	1
35	A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 1742-1742.	1.4	1
36	Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection. <i>Blood</i> , 2019, 134, 4347-4347.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Fixed duration <i>vs.</i> prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 23-30.	3.0	0
38	Potentiating Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry. <i>Blood</i> , 2007, 110, 1505-1505.	1.4	0
39	SIRP α Fc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B Cells to Macrophage-Mediated Destruction. <i>Blood</i> , 2015, 126, 2191-2191.	1.4	0
40	Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Heavy/light chain (HLC) Normalization. <i>Blood</i> , 2015, 126, 1982-1982.	1.4	0
41	Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model. <i>Blood</i> , 2016, 128, 1184-1184.	1.4	0
42	Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience. <i>Blood</i> , 2018, 132, 4614-4614.	1.4	0
43	Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?. <i>Blood</i> , 2019, 134, 5704-5704.	1.4	0